Oskars Kalējs

Prof. Oskars Kalējs is a faculty member at Rīga Stradiņš University (RSU) in the Department of Internal Medicine. His research focuses on arrhythmias, particularly atrial fibrillation, with an emphasis on genetic mechanisms, clinical outcomes of treatments, and anticoagulant therapies. He has contributed to international guidelines, including the 2022 ESC Guidelines on cardio-oncology and atrial fibrillation management. His work spans clinical trials evaluating antiarrhythmic medications, ablation techniques, and the impact of comorbidities like diabetes and obesity on cardiovascular outcomes. Prof. Kalējs collaborates with the ESC-EHRA EORP registries, developing predictive tools for arrhythmia recurrence and advancing cardioembolic stroke prevention strategies. His research also explores the historical and technological evolution of cardiac devices, such as automated external defibrillators.

Key areas of investigation include genetic factors in early-onset atrial fibrillation, the role of pulmonary vein anatomy in arrhythmia progression, and the optimization of anticoagulant therapy in high-risk patients. He has published extensively on topics ranging from machine learning applications in predicting ablation outcomes to the molecular basis of cardiac diseases. His interdisciplinary approach bridges clinical practice, genomics, and device innovation, with a focus on improving patient care and advancing cardiac electrophysiology knowledge.